KR
Keros Therapeutics, Inc.
KROS · NASDAQ
$11.17 +1.55% (+$0.17)
1M +6.58%
Market Cap $357.4M
P/E Ratio -
Div. Yield -
ROE 21.40%
Bulios Fair Price
$16.72
49.7% upside
Trenutna cena
$11.17
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica KROS trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
3/9Valuation
50 /100
Fair P/S 23.81x
P/B 1.36x
P/E N/A
Growth
40 /100
Stable Book val. growth 3.00%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 94.69%
FCF margin 322.95%
Net margin 553.88%
Quality
1 /100
Poor ROIC 35.25%
Asset turnover 0.05x
ROE 21.40%
Debt
100 /100
Low Debt/Equity 0.06x
Current ratio 21.96x
Int. coverage N/A
Stability
35 /100
Moderate Beta 1.02x
Profitable years 1
EPS volatility 91.65%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o KROS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jasbir S. Seehra
Employees
92
Headquarters
Lexington
Prihajajoči dogodki
04 NOV.
Earnings
Upcoming earnings report